Dapagliflozin’s myostatin reduction

Dapagliflozin’s myostatin reduction

Recent studies have explored the relationship between dapagliflozin"a sodium-glucose cotransporter 2 (SGLT2) inhibitor"and myostatin, a protein that inhibits muscle growth. These investigations suggest that dapagliflozin may influence myostatin levels, potentially impacting muscle mass and function.

Dapagliflozin’s Impact on Myostatin and Muscle Mass
Reduction in Myostatin Levels: A randomized controlled trial involving patients with type 2 diabetes found that dapagliflozin therapy significantly decreased circulating myostatin levels. This reduction was associated with the maintenance of skeletal muscle mass (SMM), despite overall weight loss. The study suggests that dapagliflozin’s effects on glucose metabolism and fat mass may alleviate intramuscular pathways involved in myostatin production, potentially reducing the risk of muscle atrophy.
• Exercise Mitigates Muscle Atrophy: In a study using a rat model of type 2 diabetes, dapagliflozin treatment alone led to a decrease in skeletal muscle mass. However, when combined with resistance training (RT), there was a significant increase in muscle mass and muscle fiber cross-sectional area. The combination therapy also resulted in downregulation of muscle atrophy-related genes, including myostatin. These findings suggest that while dapagliflozin may contribute to muscle atrophy, concurrent resistance exercise can mitigate these effects.

Summary

While dapagliflozin has been associated with reductions in myostatin levels, its impact on muscle mass appears to be complex and may depend on additional factors such as exercise. The combination of dapagliflozin therapy with resistance training may offer a strategy to preserve or enhance muscle mass in patients with type 2 diabetes.

• 5 mg once daily: In a 24-week randomized controlled trial, patients received 5 mg/day of dapagliflozin in addition to their conventional therapy. This regimen led to a significant reduction in serum myostatin levels and maintenance of skeletal muscle mass, despite overall weight loss.
• 10 mg once daily: Another study administered 10 mg/day of dapagliflozin over 12 weeks, resulting in an increased lean-to-total mass ratio compared to glibenclamide.

The standard therapeutic dose of dapagliflozin for managing type 2 diabetes is typically 10 mg once daily.

Pretty interesting the fact you drop weight but also reduce myostacin

SGLT2 inhibitors are genuinely interesting for metabolic health. The myostatin reduction data is preliminary, mostly in diabetic or sarcopenic populations. The cardiovascular and renal protective effects are very well-established though. Worth considering for health-conscious lifters over 45.

I track glucose continuously. Running dapagliflozin 10mg daily for 6 months. Observable effects: fasting glucose reduced by 8mg per dL, body weight down 1.8kg mostly fat per DEXA, blood pressure reduced 4 over 3 mmHg. The myostatin reduction claim requires more rigorous study design.

SGLT2 inhibitors have well-characterised cardiovascular and renal protective mechanisms beyond glycaemic control. The proposed myostatin reduction via AMPK-mTOR signalling modulation is hypothesis-generating. The glycosuric effect means 60-100 calories of glucose excreted daily. Euglycaemic DKA risk during very low carbohydrate periods is a real but manageable contraindication.